224 related articles for article (PubMed ID: 33215494)
1. Development of Indoleamine 2,3-Dioxygenase 1 Inhibitors for Cancer Therapy and Beyond: A Recent Perspective.
Feng X; Liao D; Liu D; Ping A; Li Z; Bian J
J Med Chem; 2020 Dec; 63(24):15115-15139. PubMed ID: 33215494
[TBL] [Abstract][Full Text] [Related]
2. Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and PROTAC-based degraders for cancer therapy.
Tang K; Wang B; Yu B; Liu HM
Eur J Med Chem; 2022 Jan; 227():113967. PubMed ID: 34752953
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 5-(pyridin-3-yl)-1H-indole-4,7-diones as indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
Kong KM; Zhang JW; Liu BZ; Meng GR; Zhang Q
Bioorg Med Chem Lett; 2020 Feb; 30(4):126901. PubMed ID: 31882299
[TBL] [Abstract][Full Text] [Related]
4. Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1): Probing the active site-inhibitor interactions.
Tomek P; Palmer BD; Flanagan JU; Sun C; Raven EL; Ching LM
Eur J Med Chem; 2017 Jan; 126():983-996. PubMed ID: 28011425
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel IDO1 inhibitors via structure-based virtual screening and biological assays.
Ge H; Mao L; Zhao J; Wang Y; Shi D; Yang X; Wang X; Liu H; Yao X
J Comput Aided Mol Des; 2021 May; 35(5):679-694. PubMed ID: 33905074
[TBL] [Abstract][Full Text] [Related]
6. Recent discovery of indoleamine-2,3-dioxygenase 1 inhibitors targeting cancer immunotherapy.
Weng T; Qiu X; Wang J; Li Z; Bian J
Eur J Med Chem; 2018 Jan; 143():656-669. PubMed ID: 29220788
[TBL] [Abstract][Full Text] [Related]
7. A theranostic probe of indoleamine 2,3-dioxygenase 1 (IDO1) for small molecule cancer immunotherapy.
Wu Y; Zhang Y; Chen X; Hu Y; Dong G; Guo Y; Sheng C
Eur J Med Chem; 2021 Mar; 213():113163. PubMed ID: 33482599
[TBL] [Abstract][Full Text] [Related]
8. Discovery and development of a novel N-(3-bromophenyl)-{[(phenylcarbamoyl)amino]methyl}-N-hydroxythiophene-2-carboximidamide indoleamine 2,3-dioxygenase inhibitor using knowledge-based drug design.
Yeh TK; Song JS; Chang PW; Yu JC; Chang CH; Liao FY; Tien YW; Kuppusamy R; Li AS; Chen CH; Chen CW; Lin LM; Chang HH; Huang CH; Yao JY; Wu MH; Peng YH; Hsueh CC; Hsiao WC; Chen PH; Lin CY; Hsieh SH; Shih C; Hung MS; Wu SY; Kuo CC; Ueng SH
Eur J Med Chem; 2022 Feb; 229():114043. PubMed ID: 34929581
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and Molecular Modeling Studies of N'-Hydroxyindazolecarboximidamides as Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.
Lee DH; Lee JY; Jeong J; Kim M; Lee KW; Jang E; Ahn S; Lee CH; Hwang JY
Molecules; 2017 Nov; 22(11):. PubMed ID: 29120388
[TBL] [Abstract][Full Text] [Related]
10. Identification and preliminary structure-activity relationships of 1-Indanone derivatives as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors.
Gao D; Li Y
Bioorg Med Chem; 2017 Jul; 25(14):3780-3791. PubMed ID: 28526475
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a Novel Scaffold as an Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Based on the Pyrrolopiperazinone Alkaloid, Longamide B.
Shiokawa Z; Kashiwabara E; Yoshidome D; Fukase K; Inuki S; Fujimoto Y
ChemMedChem; 2016 Dec; 11(24):2682-2689. PubMed ID: 27863031
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of immunosuppressive indoleamine 2,3-dioxygenase by targeting the heme and apo-form.
Pradhan N; Akhtar N; Nath B; Peña-García J; Gupta A; Pérez-Sánchez H; Kumar S; Manna D
Chem Commun (Camb); 2021 Jan; 57(3):395-398. PubMed ID: 33326535
[TBL] [Abstract][Full Text] [Related]
13. Spiro-Oxindole Skeleton Compounds Are Efficient Inhibitors for Indoleamine 2,3-Dioxygenase 1: An Attractive Target for Tumor Immunotherapy.
Yan D; Xu J; Wang X; Zhang J; Zhao G; Lin Y; Tan X
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563059
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Clinical Candidate (1
Kumar S; Waldo JP; Jaipuri FA; Marcinowicz A; Van Allen C; Adams J; Kesharwani T; Zhang X; Metz R; Oh AJ; Harris SF; Mautino MR
J Med Chem; 2019 Jul; 62(14):6705-6733. PubMed ID: 31264862
[TBL] [Abstract][Full Text] [Related]
15. Discovery and characterisation of hydrazines as inhibitors of the immune suppressive enzyme, indoleamine 2,3-dioxygenase 1 (IDO1).
Fung SP; Wang H; Tomek P; Squire CJ; Flanagan JU; Palmer BD; Bridewell DJ; Tijono SM; Jamie JF; Ching LM
Bioorg Med Chem; 2013 Dec; 21(24):7595-603. PubMed ID: 24262887
[TBL] [Abstract][Full Text] [Related]
16. Discovery and characterization of natural products as novel indoleamine 2,3-dioxygenase 1 inhibitors through high-throughput screening.
Guo W; Yao S; Sun P; Yang TB; Tang CP; Zheng MY; Ye Y; Meng LH
Acta Pharmacol Sin; 2020 Mar; 41(3):423-431. PubMed ID: 31197246
[TBL] [Abstract][Full Text] [Related]
17. Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.
Röhrig UF; Majjigapu SR; Vogel P; Zoete V; Michielin O
J Med Chem; 2015 Dec; 58(24):9421-37. PubMed ID: 25970480
[TBL] [Abstract][Full Text] [Related]
18. Rational design, synthesis and biological evaluation of ubiquinone derivatives as IDO1 inhibitors.
Ding Y; Tang F; Xue X; Luo J; Hussain M; Huang Y; Wang Z; Jiang H; Tu Z; Zhang J
Bioorg Chem; 2019 Aug; 89():102870. PubMed ID: 31103493
[TBL] [Abstract][Full Text] [Related]
19. Inhibition Mechanisms of Indoleamine 2,3-Dioxygenase 1 (IDO1).
Röhrig UF; Reynaud A; Majjigapu SR; Vogel P; Pojer F; Zoete V
J Med Chem; 2019 Oct; 62(19):8784-8795. PubMed ID: 31525930
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory investigation of niacin derivatives on metalloenzyme indoleamine 2,3-dioxygenase 1 for its immunomodulatory function.
Yan D; Xu J; Tan X
Metallomics; 2021 Feb; 13(3):. PubMed ID: 33638642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
